

Exhibit A
of Amendment in Response to April 19, 2007 Office
Action, Petition for a Three-Month Extension of Time
And Information Disclosure Statement
filed October 19, 2007 in

Applicant: David Baltimore et al.
Serial No.: 10/037,341
Filed: January 4, 2002



Dkt. No. 75723-ZA/JPW/GJG/PJS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David Baltimore, et al.
Serial No.: 10/037,341 Examiner: David Guzo
Filed : January 4, 2002 Group Art Unit: 1636
Title : Nuclear Factors Associated With Transcriptional Regulation

1185 Avenue of the Americas
New York, New York 10036

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

DECLARATION OF DR.INDER VERMA

I, Dr. Inder Verma, declare as follows:

1. I am the American Cancer Society Professor of Molecular Biology at The Salk Institute, Laboratory of Genetics, La Jolla, California. A copy of my *curriculum vitae* and a list of my publications are attached hereto as **Exhibit 1**.

2. I have been retained by the applicants' counsel as a technical expert in concurrent reexamination proceeding Nos. 90/007,503 and 90/007,828, as well as in this application. I have provided testimony in reexamination proceeding Nos. 90/007,503 and 90/007,828.

I. Scope of Opinion

3. I have been provided with, and asked to review, U.S. Serial No. 10/037,341, claims 90 and 91, the Office Action dated April 19, 2007, and the various references cited within that Office

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 2

Action. I have been asked to provide an analysis of the scientific evidence relied on by the Examiner to reject certain claims of the above-identified application as expressly or inherently anticipated by these references. In particular, I have been asked to provide an analysis as to whether one of skill in the art would have understood these references to describe or disclose the elements of the above-identified application claims being rejected on the basis of these references.

Where the rejection of certain claims has been made on grounds of inherency, I have been asked to analyze whether there is any basis in fact and/or technical reasoning to support a determination that elements present in these claims would necessarily result from the teachings of the cited art. For the purpose of this declaration I have understood, one skilled in this art in 1991 would have at least a doctoral degree, e.g. a Ph.D. degree, in molecular biology or a related discipline, have at least 3 years of post-doctoral training, have knowledge in cell biology, biochemistry and genetics, and be well trained in laboratory methodologies.

4. The opinions set forth in this declaration are based on my professional knowledge and expertise, as indicated in my curriculum vitae, my review of U.S. Serial No. 10/037,341, filed January 4, 2002 and the Office Action dated April 19, 2007, including the documents cited in the Office Action. For the purposes of this declaration, I have been requested to review claims 90 and 91.

II. Interpretation of the Claims

5. My interpretation of the claims is based on my understanding to how one of skill in the art would have understood the terms appearing in the claims in the context of the claims as a whole, in view of the description of the invention set forth in the patent.

6. Both of the claims under review require the act of reducing induced or activated NF- κ B activity. Claims 90 and 91 recite “reducing expression in a human cell of a gene, the expression of which has been induced” by an extracellular influence that activates NF- κ B. As such, both claims now under review require that NF- κ B activity be induced prior to the act of administering a composition that could reduce such induced or activated NF- κ B activity.

A. Inherent Anticipation rejection based on the PDR 1985, Griffith 1981 (“Griffith I”) and Griffith 1984 (Griffith II)

7. I understand that Examiner has alleged that the 1985 PDR, Griffith et al. I (1982) and Griffith et al. II (1984) inherently anticipate claim 90. I understand the Examiner’s position to be that the method being claimed in claim 90 is described in the 1985 PDR, Griffith et al. I, Griffith et al. II based on Holschermann et al. I respectfully disagree. I have reviewed the claims, the 1985 PDR, Griffith et al. I and II and Holschermann et al. and determined that none of these references disclose the method of the claims under review. In the sections which follow, I first present my observations of the 1985 PDR, Griffith et al. I and Griffith et al. II, and then present my observation of the non-prior art reference, Holschermann et al., which the April 19, 2007 Office Action purports explains these references.

1985 PDR

8. I have reviewed the Examiner’s comments in the April 19, 2007 Office Action regarding the 1985 PDR and disagree on several points. Claim 90 recites a “method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B” (emphasis added). I understand the Examiner has alleged that the 1985 PDR teaches administration of CsA to reduce activated NF- κ B activity. I find no such teaching in the 1985 PDR. The 1985 PDR provides dosage and administration instructions for the use of CsA.

Further, the 1985 PDR describes CsA as “a potent immunosuppressive agent which in animals prolongs survival of allogenic transplants involving skin, heart, kidney, pancreas, bone marrow, small intestine and lung. Sandimmune [cyclosporine] has been demonstrated to suppress some humoral immunity and to a greater extent, cell-mediated reactions such as allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, Freund’s adjuvant arthritis and graft vs. host disease in many animal species for a variety of organs.” (page 1811, third column). Importantly, the 1985 PDR discloses a specific protocol of administration: “the initial dose of Sandimmune (cyclosporine) Oral Solution should be given 4-12 hours prior to transplantation..” (emphasis added, page 1813, first column). Therefore, the 1985 PDR cannot teach a method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B as recited by claim 90.

Griffith et al. I

9. I have reviewed the Examiner’s comments in the April 19, 2007 Office Action regarding Griffith et al. I and disagree on several points. Claim 90 recites a “method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B” (emphasis added). I understand the Examiner has alleged that Griffith et al. I teach administration of CsA to reduce NF- κ B activity in cardiac transplantation recipients. I find no such teaching in Griffith et al. I. Griffith et al. I teach the administration of cyclosporine “orally just before operation” (page 324, second column). Even if one assumes that surgery induces NF- κ B, which I am not certain that it does, administration of CsA prior to surgery is analogous to pretreatment and therefore at best prevents activation of NF- κ B. Therefore, Griffith et al. I cannot teach a method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B as cited in claim 90.

Griffith II

10. I have reviewed the Examiner's comments in the April 19, 2007 Office Action regarding Griffith et al. II and disagree on several points. Claim 90 recites a "method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B" (emphasis added). I understand the Examiner has alleged that Griffith et al. II teach administration of CsA to reduce NF- κ B activity in cardiac transplantation recipients. I find no such teaching in Griffith et al. II. Griffith et al. II teach the administration of cyclosporine "orally 1 to 4 hours preoperatively and continued orally, or by nasogastric tube, every 12 hours postoperatively" (page 952, second column). Even if one assumes that surgery induces NF- κ B, which I am not certain that it does, administration of CsA prior to surgery is analogous to pretreatment and therefore at best prevents activation of NF- κ B. Therefore, Griffith et al. II cannot teach, regardless of what Holschermann et al. disclose, a method for reducing expression in a human cell of a gene, the expression of which has been induced by an external influence that activates NF- κ B as recited by claims 89 and 90.

Holschermann

11. The Examiner cited Holschermann et al. Circulation (1997) 96(12):4232-4238 to purportedly explain what occurred in each of Griffith et al. I, Griffith et al. II and upon use of CsA as taught in the 1985 PDR. However, I do not understand how Holschermann et al. can explain what necessarily occurred in any of the three prior art references cited by the Examiner. There are critical points that differ between Holschermann et al. and the prior art references. There is no evidence that NF- κ B had been activated in patients prior to the administration of CsA. As I discussed in paragraph 10 above, even if surgery were to induce NF- κ B, and I am not certain that

it does, the administration of CsA prior to surgery as is taught in the prior art is analogous to pretreatment and therefore at best prevents activation of NF- κ B, but does not reduce induced or activated NF- κ B activity as required by the claims under review.

12. Further, the protocols differ greatly between the prior art references and Holschermann et al. The protocol used by Holschermann et al. deviates greatly from the protocols outlined by the 1985 PDR, Griffith et al. I and Griffith et al. II. Patients in the prior art studies did not receive the same drug cocktail as those in Holschermann et al. and therefore it is unclear what effect, if any, CsA had on the patients. One skilled in the art would expect a cocktail of different active drugs, as described, to result in the different patient outcomes. It is unreasonable to conclude that the results observed using one cocktail of active drugs in Holschermann et al. could possibly explain what previously happened when a different cocktail of active drugs was used in the prior art.

13. Further, the timing of administration of the drug cocktails differs greatly between the prior art and Holschermann et al. Holschermann et al. do not begin CsA treatment until 3 to 4 days after surgery, a highly relevant departure from the studies described in the prior art. Therefore Holschermann et al. cannot be used to explain what occurred in the prior art.

14. Moreover, as someone of skill in the art, I do not understand the experiments described in Holschermann et al. to demonstrate that the administration of CsA reduces induced or activated NF- κ B. Holschermann et al. discloses a protocol wherein "PBMCs and monocytes/macrophages were prepared from blood samples drawn from cardiac transplant recipients before and after daily CsA administration" (page 4234, first column). Holschermann et al. go on to disclose that "measurement of the corresponding CsA plasma concentration in each blood sample revealed an increase of CsA blood levels from 233 ng/mL...in the sample before daily CsA administration" (page 4234, second column) which indicates that CsA was always present in the blood.

15. Further, I have critically examined Figures 3 and 4 of Holschermann et al. which the Examiner has pointed to in alleged confirmation of the ability of CsA to reduce the levels of a protein, tissue factor (TF) which is purported to be regulated by NF- κ B. I respectfully disagree with the interpretation of the results set forth in the April 19, 2007 Office Action. First, in Figure 3 (a copy of which is attached hereto as **Exhibit 2**), the sample loaded into lane 2, which is derived from blood collected from patients prior to the daily CsA administration has no detectable level of mRNA. Further, it is only after a six hour incubation can one observe a faint TF mRNA band, as indicated in lane 3. Notably, the sample collected from a patient after CsA administration and incubated for 6 hours shows no reduction in band intensity as shown in lane 6. It is only when the sample is incubated with LPS for 6 hours, can a prominent band be observed in lane 4, indicating an increase in TF mRNA transcription. These results demonstrate that the administration of CsA prevented the induction of TF mRNA by LPS as is indicated by the faint band in lane 7. Therefore, Figure 3 of Holschermann et al. shows that CsA cannot reduce existing TF transcription, though it appears to prevent activation of TF.

16. Further, I have compared these TF mRNA transcription results with those presented in Figure 4 and I disagree with the interpretation of the data as set forth in the April 19, 2007 Office Action. First, the samples depicted in the “prior to” panel cannot correlate with a sample “prepared from blood mononuclear cells freshly isolated from transplant recipients before....CsA administration” (Figure 4, legend). If this were correct, Figure 3, lane 2, would depict the presence of TF mRNA, but it does not. The lack of activated TF mRNA, which is purported to be regulated by NF- κ B, in samples obtained from patients prior to CsA administration indicates there is no activated NF- κ B. The only conclusion that could correlate the results in Figure 3 to Figure 4 is that the samples obtained prior to CsA administration were incubated for 6 hours in the presence of LPS to stimulate NF- κ B activity. In fact, in the legend for Table 2, such a step is

described: “Mononuclear cell were isolated from peripheral blood samples of heart transplant recipients before and 4 hours after CsA administration, respectively, and assayed for TF activity after 6 hours of incubation with LPS” (page 4235). I therefore conclude that the only interpretation that can reconcile the intense NF- κ B bands observed in the “prior to” sample in Figure 4 with the results shown in Figure 3 is that the samples underwent the 6 hour incubation with LPS. Otherwise, the disconnect between the lack of TF transcription (Figure 3, lane 2) compared to intense NF- κ B bands observed in the “prior to” samples in Figure 4 still exists. Since NF- κ B has been shown to activate transcription of TF, the only reasonable explanation is the one provided above. Consequently, not only did Holschermann et al. not carry out the therapy protocols set forth in the prior art, but the data obtained by Holschermann et al. does not demonstrate that CsA reduced induced NF- κ B activity.


Non-reproducibility of Experiments

17. I do not understand the prior art references, 1985 PDR, Griffith et al. I and Griffith et al. II to provide enough detail to enable of one skill in the art to repeat their studies and arrive at the same results. The 1985 PDR provides dosage and administration instructions for the use of cyclosporine A. I understand, as one skilled in the art, that if I practice the method described in the 1985 PDR, I will observe a number of non-responsive patients or patients who exhibit adverse reactions (see table, page 1812). Therefore, the inherent variability in patient response to CsA and lack of access to the same patients populations used in these studies render it impossible for one to repeat the studies described in the prior art and obtain the same results. The 1985 PDR notes that “several study centers have found blood monitoring of cyclosporine useful in patient management” (page 1813, second column) and Griffith et al. II emphasizes this point, noting “the principal message is the lack of correlation between the dose of cyclosporine and the whole-blood level. Monitoring of the blood level is necessary to ensure that the administered dose provides a

Applicants: David Baltimore et al.
Serial No.: 10/037,341
Filed : January 4, 2002
Page 9

significant level of circulating cyclosporine" (page 954, first column). Thus, the lack of availability of the patient populations used in prior studies as well as the inherent variability in patients' responses to CsA would not enable one to practice the 1985 PDR, Griffith et al. I and Griffith et al. II studies and arrive at the same result.

18. I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application.


Inder Verma, Ph.D.

Oct 19 / 2002
Date

Exhibit 1
of Dr. Verma Declaration
filed October 19, 2007 in

Applicant: David Baltimore et al.
Serial No.: 10/037,341
Filed: January 4, 2002



INDER M. VERMA
CURRICULUM VITAE

Address:	Laboratory of Genetics The Salk Institute 10010 North Torrey Pines Road La Jolla, CA 92037	Home:	1620 Valdes Drive La Jolla, CA 93037
Tel:	(858) 453-4100 x1462		
Fax:	(858) 558-7454		
E-mail:	verma@salk.edu		
Date of Birth:	November 28, 1947		
Place of Birth:	Sangrur, Punjab, India		
Citizenship:	U.S. Citizen		

EDUCATION:

1971-1974	Department of Biology, Massachusetts Institute of Technology, Cambridge, MA. Postdoctoral fellow (with Dr. D. Baltimore)
1967-1971	The Weizmann Institute of Science, Rehovot, Israel, Ph.D. Biochemistry
1964-1966	Lucknow University, India M.Sc. Biochemistry

PROFESSIONAL EXPERIENCE:

6/95 - Present	Professor, Laboratory of Genetics, The Salk Institute, La Jolla, California
2/85 - 6/95	Professor, Molecular Biology and Virology Laboratory, The Salk Institute
7/83 - Present	Adjunct Professor, Department of Biology, University of California, San Diego
2/83 - 1/85	Senior Member, Molecular Biology and Virology Laboratory, The Salk Institute
7/79 - 1/83	Adjunct Associate Professor, Department of Biology, University of California, San Diego
1/79 - 1/83	Associate Professor, The Salk Institute
4/74 - 1/79	Assistant Professor, The Salk Institute

HONORS AND AWARDS:

2006	Member of the American Philosophical Society
2006	AAAS Fellow
2005	Foreign Fellow, Indian National Science Academy (INSA)
2000	Fellow, American Academy of Arts and Sciences
1999	Member, Institute of Medicine of The National Academy of Sciences (USA)
1998	Associate Member, European Molecular Biology Organization (EMBO)
1997	Member, The National Academy of Science (USA)
1997	Foreign Fellow, The National Academy of Sciences, India
1997	Fellow, American Academy of Microbiology
1995	Member, The Third World Academy of Sciences
1995	Charaka Award of The Association of Indians in America

1993	Thrombosis Research Institute, London, Annual Award for 1993
1990	American Cancer Society Professor of Molecular Biology
1988	NIH Outstanding Investigator Award
1987	NIH Merit Award
1985	Medal for Outstanding Scientist of North American Scientists of Indian Origin
1970 - 1973	Fellow of the Jane Coffin Childs Memorial Fund for Medical Research
1967 - 1970	Reverend Solomon B. Caulker Memorial Fellowship
1964 - 1966	First in order of merit in M.Sc.

EXTRACURRICULAR SERVICES:

2006 – 2007	Chair of the Faculty and Academic Council of The Salk Institute
2001 - Present	Editorial Board of the Proceedings of the National Academy of Sciences (USA)
2001 – Present	Ceregene, Inc., member, Board of Directors and Scientific Advisory Board
2001 – Present	Xenogen, Scientific Advisory Board
2001 – Present	Jubilant Biosys, Ltd., member, Scientific Advisory Board and Board of Directors
1999 – 2004	Editor-in-Chief, Molecular Therapy (journal of the American Society for Gene Therapy)
1998 – 2001	Editorial Board of Genetic Medicine
2000 – 2001	President, American Society for Gene Therapy
1997 - Present	Agensys, Santa Monica, CA, member, Scientific Advisory Board
1997 - Present	Cell Genesys, Inc., Foster City, CA, member, Board of Directors and Chairman, Scientific Advisory Board,
1997 - 2001	Arcaris Pharmaceuticals, Salt Lake City, UT, member, Scientific Advisory Board
1995 - 1999	Editor, GENE
1995 - 1999	Member, Scientific Advisory Board of MA Bioservices, Rockville, MD
1994 - Present	Editor, Gene Expression
1998	Member, American Society for Virology
2000 - Present, 1994 – 1998, &	
1989 - 1991	Member, Board of Trustees, The Salk Institute
1993 - 1999	Editor, Journal of Virology
1993 - 2001	Founder and Chairman of the Scientific Advisory Board, Signal Pharmaceuticals, Inc., San Diego, CA
1989 - 1998	Member Academic Council of The Salk Institute
1983 - Present	Coordinator of the Scientific Advisory Committee established by the Prime Minister of India for the Department of Biotechnology
1990 - 1997	Founder and Chairman of the Scientific Advisory Board, Somatix Therapy Corporation, Alameda, CA
2001 – 2002, 1996 - 1997 &	
1991 - 1992	Chairman of the Faculty and Academic Council of The Salk Institute
1994 - 1995 &	
1989 - 1990	Vice Chairman: Faculty and Academic Council of The Salk Institute

REVIEW COMMITTEES:

2001 – Present	Fred Hutchinson Cancer Research Center, Scientific Advisory Board
2000 – Present	Cleveland Clinic Foundation, External Advisory Board
1998 - Present	Wellcome Trust Fellowship Review Committee
1991 - Present	General Motors Sloan Selection Committee
1997 – 2006	Damon Runyon Scholar Award Committee
1997	Scientific Advisory Committee, Ben May Cancer Institute, University of Chicago
1997	Scientific Advisory Committee, Leukemia Society of America
1995	Chairman, Ad Hoc Review Committee for the Recombinant DNA Advisory Committee
1994	Quinquennial Review Committee for ICRF, London
1993	American Cancer Society Postdoctoral Fellowship Screening Committee
1992	Institute of Biomedical Sciences Scientific External Research Review, Taipei, Taiwan
1989-1993	Member, Scientific Advisory Committee of the Damon Runyon-Walter Winchell Cancer Research Fund
1986-1989	Chairman, Advisory Committee on Cell & Developmental Biology, American Cancer Society
1981-1985	Member, Virology Study Section, NIH

PUBLICATIONS:

1. Edelman M, Verma IM, Littauer UZ 1970 Mitochondrial ribosomal RNA from *Aspergillus nidulans*: characterization of a novel molecular species. J Mol Biol 49:67-83
2. Verma IM, Edelman M, Herzberg M, Littauer UZ 1970 Size determination of mitochondrial ribosomal RNA from *Aspergillus nidulans* by electron microscopy. J Mol Biol 52:137-140
3. Edelman M, Verma IM, Herzog R, Galun E, Littauer Uz 1971 Physico-chemical properties of mitochondrial ribosomal RNA from fungi. Eur J Biochem 19:372-378
4. Edelman M, Verma IM, Saya D, Littauer UZ 1971 Optical absorbance properties of mitochondrial ribosomal RNA. Biochem Biophys Res Commun 42:208-213
5. Verma IM, Edelman M, Littauer UZ 1971 A comparison of nucleotide sequences from mitochondrial and cytoplasmic ribosomal RNA of *Aspergillus nidulans*. Eur J Biochem 19:124-129
6. Verma IM, Kay CM, Littauer Uz 1971 Circular dichroism of mitochondrial ribosomal RNA from *Trichoderma viride*. FEBS Letters 12:317-231
7. Verma IM, Meuth NL, Bromfield E, Manly K, Baltimore D 1971 A covalently-linked RNA-DNA molecule as the initial product of the NRA tumor virus DNA polymerase. Nature 233:131-134
8. Forget BG, Marotta CA, Verma IM, McCaffrey RP, Baltimore D, Weissman SM 1972 Nucleotide sequence analysis of human globin messenger RNA. Blood 40:961
9. Verma IM, Meuth NL, Baltimore D 1972 The covalent linkage between RNA primer and DNA product of the avian myeloblastosis virus DNA polymerase. J Virol 10:622-627
10. Verma IM, Temple GF, Fan H, Baltimore D 1972 In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nature New Biol 235:163-167
11. Berns AJM, Blumenthal H, Kaufman S, Verma IM 1973 Synthesis of NDA complementary to 14S calf lens crystallin messenger RNA by reverse transcriptase. Biochem Biophys Res Commun 52:1013-1019
12. Gibson W, Verma IM 1974 Studies on the reverse transcriptase of RNA tumor viruses. II. Structural relatedness of the two subunits of avian RNA tumor viruses. Proceedings of the National Academy of Sciences (USA) 71:4991-4994
13. Marotta CA, Forget BG, Weissman SM, Verma IM, McCaffrey RP, Baltimore D 1974 Nucleotide sequences of human globin messenger RNA. Proceedings of the National Academy of Sciences (USA)

71:2300-2304

14. Verma IM, Firtel RA, Lodish FH, Baltimore D 1974 Synthesis of DNA complementary to cellular slime mold messenger RNA by reverse transcriptase. *Biochemistry* 13:3917
15. Verma IM, Mason WS, Drost SD, Baltimore D 1974 DNA polymerase activity from two temperature-sensitive mutants of Rous sarcoma virus is thermolabile. *Nature* 251:27-31
16. Verma IM, Meuth NL, Fan H, Baltimore D 1974 Hamster leukemia virus: lack of endogenous DNA synthesis and unique structure of its DNA polymerase. *J Virol* 13:1075-1082
17. Tronick SR, Stephenson JR, Verma IM, Aaronson SA 1975 A thermolabile reverse transcriptase of a mammalian leukemia virus mutant temperature-sensitive in its replication and sarcoma virus helper function. *J Virol* 16:1476-1482
18. Verma IM 1975 Studies on reverse transcriptase of RNA tumor viruses III. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. *J Virol* 15:843-854
19. Verma IM 1975 Studies on the reverse transcriptase of RNA tumor viruses: I. Localization of thermolabile DNA polymerase and ribonuclease H activities on one polypeptide. *J Virol* 15:121-126
20. Verma IM, Varmus HE, Hunter E 1976 Characterization of "early" temperature-sensitive mutants of avian sarcoma viruses: Biological properties, thermolability of reverse transcriptase in vitro, and synthesis of viral DNA in infected cells. *Virology* 74:16-29
21. Hu S, Davidson N, Verma IM 1977 A heteroduplex study of the sequence relationships between the RNA's of M-MSV and M-MLV. *Cell* 10:469-477
22. Verma IM 1977 The reverse transcriptase. *Biochim Biophys Acta* 473:1-38
23. Chien Y-H, Verma IM, Shih TY, Scalnick EM, Davidson N 1978 Heteroduplex analysis of the sequence relations between the RNAs of mink cell focus-inducing and murine leukemia viruses. *J Virol* 28:352-360
24. Fan H, Verma IM 1978 Size analysis and relationship of murine leukemia virus-specific mRNA's: evidence for transposition of sequences during synthesis and processing of subgenomic mRNA. *J Virol* 26:468-478
25. Lai M-HT, Verma IM, Tronick SR, Aaronson SA 1978 Mammalian retrovirus-associated RNase H is virus coded. *J Virol* 27:823-825
26. Lai MT, Verma IM 1978 Reverse transcriptase of RNA tumor viruses. V. In vitro proteolysis of reverse transcriptase from avian myeloblastosis virus and isolation of a polypeptide manifesting only RNase H activity. *J Virol* 25:652-663
27. Verma IM 1978 Genome organization of RNA tumor viruses. I. In vitro synthesis of full genome-length single-stranded and double-stranded viral DNA transcripts. *J Virol* 26:615-629
28. Verma IM, McKennett M 1978 Genome organization of RNA tumor viruses: II. Physical maps of the in vitro synthesized Moloney murine leukemia virus DNA by restriction endonucleases. *J Virol* 26:630-645
29. Bosselman RA, van Griensven LJLD, Vogt M, Verma IM 1979 Genome organization of retroviruses. VI. Heteroduplex analysis of ectopic and xenotropic sequences of Moloney mink cell focus-inducing viral RNA obtained from either a cloned isolate or a thymoma cell line. *J Virol* 32:968-978
30. Chien Y-H, Lai M, Shih TY, Verma IM, Scolnick EM, Roy-burman P, Davidson N 1979 Heteroduplex analysis of the sequence relationships between the genomes of Kirsten and Harvey sarcoma viruses, their respective parental murine leukemia viruses, and the rat endogenous 30S RNA. *J Virol* 31:752-760
31. Chien Y-H, Verma IM, Duesberg PH, Davidson N 1979 Heteroduplex analysis of the RNA of clone 3 Moloney murine sarcoma virus. *J Virol* 32:1028-1032
32. Verma IM 1979 Genome organization of retroviruses. III. Restriction endonuclease cleavage maps of mouse sarcoma virus double-stranded DNA synthesized in vitro. *Nucl Acid Res* 6:1863-1867
33. Berns AJ, Lai MH, Bosselman RA, McKennett MA, Bachelier LT, Fan H, Maandag EC, van der Putten H, Verma IM 1980 Molecular cloning of unintegrated and a portion of integrated Moloney murine leukemia viral DNA in bacteriophage lambda. *J Virol* 36:254-263
34. Bosselman RA, Van Griensven LJLD, Vogt M, Verma IM 1980 Genome organization of retroviruses. IX. Analysis of the genomes of Friend spleen focus-forming (F-SFFV) and helper murine leukemia viruses by heteroduplex-formation. *Virology* 102:234-239
35. Bosselman RA, Verma IM 1980 Genome organization of retroviruses. V. In vitro synthesized Moloney murine leukemia viral DNA has long terminal redundancy. *J Virol* 33:487-493
36. Jones M, Bosselman RA, van der Hoorn FA, Berns A, Fan H, Verma IM 1980 Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. *Proceedings of the National Academy of Sciences (USA)* 77:2651-2655

37. Lai MT, Verma IM 1980 Genome organization of retroviruses. VII. Infection by double-stranded DNA synthesized in vitro from Moloney murine leukemia virus generates a virus indistinguishable from the original virus used in reverse transcription. *Virology* 100:194-198
38. Lai MT, Verma IM 1980 Genome organization of retroviruses. VIII. Non-producer cell lines of mouse fibroblasts transformed by Moloney murine sarcoma virus DNA synthesized in vitro. *Virology* 104:407-417
39. Sutcliffe JG, Shinnick TM, Verma IM, Lenner RA 1980 Nucleotide sequence of Moloney leukemia virus: 3' End reveals details of replication, analogy to bacterial transposons, and an unexpected gene. *Proceedings of the National Academy of Sciences (USA)* 77:3302-3306
40. Van Beveren C, Goddard JG, Berns A, Verma IM 1980 Structure of Moloney murine leukemia viral DNA: Nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. *Proceedings of the National Academy of Sciences (USA)* 77:3307-3311
41. Verma IM, Lai MT, Bosselman RA, McKenney MA, Fan H, Berns A 1980 Molecular cloning of unintegrated Moloney mouse sarcoma-virus DNA in bacteriophage-lambda. *Proceedings of the National Academy of Sciences (USA)* 77:1773-1777
42. Fuhrman S, Van Beveren C, Verma IM 1981 Identification of an RNA polymerase II initiation site in the long terminal repeat of Moloney murine leukemia viral DNA. *Proceedings of the National Academy of Sciences (USA)* 78:5411-5415
43. Papkoff J, Lai M-HT, Hunter T, Verma IM 1981 Analysis of transforming gene products of moloney murine sarcoma virus. *Cell* 27:109-119
44. Van Beveren C, Galleshaw JA, Jonas V, Berns AJM, Doolittle RF, Donoghue DJ, Verma IM 1981 Nucleotide sequence and formation of the transforming gene of a mouse sarcoma virus. *Nature* 289:258-262
45. Van Beveren C, van Straaten F, Galleshaw JA, Verma IM 1981 Nucleotide sequence of the genome of a murine sarcoma virus. *Cell* 27:97-108
46. Van der Putten H, Quint W, van Raaij J, Robanus-Maandag E, Verma IM, Berns A 1981 M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors. *Cell* 24:729-739
47. Bosselman RA, Van Straaten F, Van Beveren C, Verma IM, Vogt M 1982 Analysis of the *env* gene of a molecularly cloned and biologically active Moloney mink cell focus-forming proviral DNA. *J Virol* 44:19-31
48. Curran T, Peters G, Van Beveren C, Teich NM, Verma IM 1982 FBJ-murine osteosarcoma virus: Identification and molecular cloning of biologically active proviral DNA. *J Virol* 44:674-682
49. Doehmer J, Barinaga M, Vale W, Rosenfeld MG, Verma IM, Evans RM 1982 Introduction of rat growth hormone gene into mouse fibroblasts via a retroviral DNA vector: Expression and regulation. *Proceedings of the National Academy of Sciences (USA)* 79:2286-2272
50. Muller R, Slamon DJ, Tremblay JM, Cline MJ, Verma IM 1982 Differential expression of oncogenes during pre- and postnatal development of the mouse. *Nature* 299:640-644
51. Papkoff J, Verma IM, Hunter T 1982 Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. *Cell* 29:417-426
52. Van Beveren C, Rands E, Chattopadhyay SK, Lowy DR, Verma IM 1982 Long terminal repeat of murine retroviral DNAs: Sequence analysis, host-proviral junctions and preintegration site. *J Virol* 41:541-556
53. Curran T, MacConnell WP, van Straaten F, Verma IM 1983 Structure of FBJ murine osteosarcoma virus genome: Molecular cloning of its associated helper virus and the cellular homolog of the *v-fos* gene from mouse and human cells. *Mol Cell Biol* 3:914-921
54. Jolly DJ, Estey AC, Subramani S, Friedmann T, Verma IM 1983 Elements in the long terminal repeat of murine retroviruses enhances stable transformation by thymidine kinase gene. *Nucl Acids Res* 11:1855-1872
55. MacConnell HP, Verma IM 1983 Expression of FBJ-MSV oncogene (*fos*) product in bacteria. *Virology* 131:367-372
56. Miller AD, Jolly DJ, Friedmann T, Verma IM 1983 A transmissible retrovirus expressing human hypoxanthine phosphoribosyl transferase (HPRT): Gene transfer into cells obtained from humans deficient in HPRT. *Proceedings of the National Academy of Sciences (USA)* 80:4709-4713
57. Muller R, Slamon DJ, Adamson ED, Tremblay JM, Muller D, Cline MJ, Verma IM 1983 Transcription of c-onc genes *c-ras* and *c-fms* during mouse development. *Mol Cell Biol* 3:1062-1069
58. Muller R, Tremblay JM, Adamson ED, Verma IM 1983 Tissue and cell type-specific expression of two human c-onc genes. *Nature* 304:454-456
59. Muller R, Verma IM, Adamson ED 1983 Expression of c-onc genes: c-fos transcripts accumulate to high

- levels during development of mouse placenta, yolk sac and amnion. *Embo J* 2:679-684
60. Van Beveren C, van Straaten F, Curran T, Muller R, Verma IM 1983 Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. *Cell* 32:1241-1255
61. van Straaten F, Muller R, Curran T, Van Beveren C, Verma IM 1983 Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. *Proc Natl Acad Sci U S A* 80:3183-3187
62. Barker PE, Rabin M, Watson M, Breg WR, Ruddle FH, Verma IM 1984 Human c-fos oncogene mapped within chromosomal region 14q21----q31. *Proc Natl Acad Sci U S A* 81:5826-5830
63. Cochran BH, Zullo J, Verma IM, Stiles CD 1984 Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. *Science* 226:1080-1082
64. Curran T, Miller AD, Zokas L, Verma IM 1984 Viral and cellular fos proteins: a comparative analysis. *Cell* 36:259-268
65. Curran T, Verma IM 1984 FBR murine osteosarcoma virus. I. Molecular analysis and characterization of a 75,000-Da gag-fos fusion product. *Virology* 135:218-228
66. Kruijer W, Cooper JA, Hunter T, Verma IM 1984 Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. *Nature* 312:711-716
67. Lin CR, Chen WS, Kruijer W, Stolarsky LS, Weber W, Evans RM, Verma IM, Gill GN, Rosenfeld MG 1984 Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. *Science* 224:843-848
68. Miller AD, Curran T, Verma IM 1984 c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. *Cell* 36:51-60
69. Miller AD, Eckner RJ, Jolly DJ, Friedmann T, Verma IM 1984 Expression of a retrovirus encoding human HPRT in mice. *Science* 225:630-632
70. Miller AD, Ong ES, Rosenfeld MG, Verma IM, Evans RM 1984 Infectious and selectable retrovirus containing an inducible rat growth hormone minigene. *Science* 225:993-998
71. Miller AD, Verma IM 1984 Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1). *J Virol* 49:214-222
72. Muller R, Verma IM 1984 Expression of cellular oncogenes. *Curr Top Microbiol Immunol* 112:73-115
73. Slamon DJ, deKernion JB, Verma IM, Cline MJ 1984 Expression of cellular oncogenes in human malignancies. *Science* 224:256-262
74. Van Beveren C, Enami S, Curran T, Verma IM 1984 FBR murine osteosarcoma virus. II. Nucleotide sequence of the provirus reveals that the genome contains sequences acquired from two cellular genes. *Virology* 135:229-243
75. Verma IM 1984 From c-fos to v-fos. *Nature* 308:317
76. Curran T, Van Beveren C, Verma IM 1985 Viral and cellular fos proteins are complexed with a 39,000-dalton cellular protein. *Mol Cell Biol* 5:167-172
77. Deschamps J, Meijlink F, Verma IM 1985 Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. *Science* 230:1174-1177
78. Deschamps J, Mitchell RL, Meijlink F, Kruijer W, Schubert D, Verma IM 1985 Proto-oncogene fos is expressed during development, differentiation, and growth. *Cold Spring Harb Symp Quant Biol* 50:733-745
79. Kruijer W, Schubert D, Verma IM 1985 Induction of the proto-oncogene fos by nerve growth factor. *Proc Natl Acad Sci U S A* 82:7330-7334
80. Meijlink F, Curran T, Miller AD, Verma IM 1985 Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. *Proc Natl Acad Sci U S A* 82:4987-4991
81. Miller AD, Law MF, Verma IM 1985 Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. *Mol Cell Biol* 5:431-437
82. Miller AD, Verma IM, Curran T 1985 Deletion of the gag region from FBR murine osteosarcoma virus does not affect its enhanced transforming activity. *J Virol* 55:521-526
83. Mitchell RL, Zokas L, Schreiber RD, Verma IM 1985 Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. *Cell* 40:209-217
84. van der Putten H, Botteri FM, Miller AD, Rosenfeld MG, Fan H, Evans RM, Verma IM 1985 Efficient insertion of genes into the mouse germ line via retroviral vectors. *Proc Natl Acad Sci U S A* 82:6148-6152

85. Botteri FM, van der Putten H, Miller AD, Fan H, Verma IM 1986 Recombinant retroviruses in transgenic mice. *Ann N Y Acad Sci* 478:255-268
86. Coussens L, Van Beveren C, Smith D, Chen E, Mitchell RL, Isacke CM, Verma IM, Ullrich A 1986 Structural alteration of viral homologue of receptor proto-oncogene *fms* at carboxyl terminus. *Nature* 320:277-280
87. Kruijer W, Skelly H, Botteri F, van der Putten H, Barber JR, Verma IM, Leffert HL 1986 Proto-oncogene expression in regenerating liver is simulated in cultures of primary adult rat hepatocytes. *J Biol Chem* 261:7929-7933
88. Mitchell RL, Henning-Chubb C, Huberman E, Verma IM 1986 *c-fos* expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages. *Cell* 45:497-504
89. Verma IM 1986 Proto-oncogene *fos*: a multifaceted gene. *Trends in Genetics* 2:93-96
90. Anson DS, Hock RA, Austen D, Smith KJ, Brownlee GG, Verma IM, Miller AD 1987 Towards gene therapy for hemophilia B. *Mol Biol Med* 4:11-20
91. Barber JR, Sassone-Corsi P, Verma IM 1987 Proto-oncogene *fos*: factors affecting expression and covalent modification of the gene product. *Ann N Y Acad Sci* 511:117-130
92. Barber JR, Verma IM 1987 Modification of *fos* proteins: phosphorylation of *c-fos*, but not *v-fos*, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. *Mol Cell Biol* 7:2201-2211
93. Billestrup N, Mitchell RL, Vale W, Verma IM 1987 Growth hormone-releasing factor induces *c-fos* expression in cultured primary pituitary cells. *Mol Endocrinol* 1:300-305
94. Howell SB, Murphy MP, Johnson J, Wamsley P, Verma I 1987 Gene therapy for thioguanine-resistant human leukemia. *Mol Biol Med* 4:157-168
95. McIvor RS, Johnson MJ, Miller AD, Pitts S, Williams SR, Valerio D, Martin DW, Jr., Verma IM 1987 Human purine nucleoside phosphorylase and adenosine deaminase: gene transfer into cultured cells and murine hematopoietic stem cells by using recombinant amphotropic retroviruses. *Mol Cell Biol* 7:838-846
96. Sassone-Corsi P, Verma IM 1987 Modulation of *c-fos* gene transcription by negative and positive cellular factors. *Nature* 326:507-510
97. Van Beveren C, Mitchell RL, Henning-Chubb C, Huberman E, Verma IM 1987 Expression of the *c-fos* gene during differentiation. *Adv Exp Med Biol* 213:263-274
98. Verma IM, Graham WR 1987 The *fos* oncogene. *Adv Cancer Res* 49:29-52
99. Verma IM, Sassone-Corsi P 1987 Proto-oncogene *fos*: complex but versatile regulation. *Cell* 51:513-514
100. Barber JR, Sassone-Corsi P, Verma IM 1988 Proto-oncogene *fos* expression and post-translational modification. *Prog Clin Biol Res* 266:23-37
101. De Togni P, Niman H, Raymond V, Sawchenko P, Verma IM 1988 Detection of *fos* protein during osteogenesis by monoclonal antibodies. *Mol Cell Biol* 8:2251-2256
102. Fujii M, Sassone-Corsi P, Verma IM 1988 *c-fos* promoter trans-activation by the *tax1* protein of human T-cell leukemia virus type I. *Proc Natl Acad Sci U S A* 85:8526-8530
103. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM 1988 Induction of proto-oncogene *JUN/AP-1* by serum and TPA. *Nature* 334:629-631
104. Sassone-Corsi P, Lamph WW, Kamps M, Verma IM 1988 *fos*-associated cellular p39 is related to nuclear transcription factor *AP-1*. *Cell* 54:553-560
105. Sassone-Corsi P, Ransone LJ, Lamph WW, Verma IM 1988 Direct interaction between *fos* and *jun* nuclear oncoproteins: role of the 'leucine zipper' domain. *Nature* 336:692-695
106. Sassone-Corsi P, Sisson JC, Verma IM 1988 Transcriptional autoregulation of the proto-oncogene *fos*. *Nature* 334:314-319
107. Sassone-Corsi P, Visvader J, Ferland L, Mellon PL, Verma IM 1988 Induction of proto-oncogene *fos* transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. *Genes Dev* 2:1529-1538
108. St. Louis D, Verma I 1988 An alternative approach to somatic cell gene therapy. *Proc Natl Acad Sci U S A* 85:3150-3154
109. Visvader J, Sassone-Corsi P, Verma IM 1988 Two adjacent promoter elements mediate nerve growth factor activation of the *c-fos* gene and bind distinct nuclear complexes. *Proc Natl Acad Sci U S A* 85:9474-9478
110. Bull P, Hunter T, Verma IM 1989 Transcriptional induction of the murine *c-rel* gene with serum and phorbol-12-myristate-13-acetate in fibroblasts. *Mol Cell Biol* 9:5239-5243

111. Fujii M, Shalloway D, Verma IM 1989 Gene regulation by tyrosine kinases: src protein activates various promoter, including c-fos. *Mol Cell Biol* 9:2493-2499
112. Malone RW, Felgner PL, Verma IM 1989 Cationic liposome-mediated RNA transfection. *Proceedings of the National Academy of Sciences (USA)* 86:6077-6081
113. Ransone LJ, Verma IM 1989 Association of nuclear oncoproteins fos and jun. *Curr Opin Cell Biol* 1:536-540
114. Ransone LJ, Visvader J, Sassone-Corsi P, Verma IM 1989 Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. *Genes Dev* 3:770-781
115. Raymond V, Atwater JA, Verma IM 1989 Removal of an mRNA destabilizing element correlates with the increased oncogenicity of proto-oncogene fos. *Oncogene Res* 5:1-12
116. Sassone-Corsi P, Der CJ, Verma IM 1989 ras-Induced neuronal differentiation of PC12 cells: Possible involvement of fos and jun. *Mol Cell Biol* 9:3174-3183
117. Valerio D, Einerhand MP, Wamsley PM, Bakx TA, Li CL, Verma IM 1989 Retrovirus-mediated gene transfer into embryonal carcinoma and hemopoietic stem cells: expression from a hybrid long terminal repeat. *Gene* 84:419-427
118. Visvader J, Verma IM 1989 Differential transcription of exon 1 of the human c-fms gene in placental trophoblasts and monocytes. *Mol Cell Biol* 9:1336-1341
119. Atwater JA, Wisdom R, Verma IM 1990 Regulated mRNA stability. *Annu Rev Genet* 24:519-541
120. Axelrod JH, Read M, Brinkhous KM, Verma IM 1990 Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. *Proceedings of the National Academy of Sciences (USA)* 86:8897-8901
121. Bull P, Morley KL, Hoekstra MF, Hunter T, Verma IM 1990 The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. *Mol Cell Biol* 10:5473-5485
122. Dwarki VJ, Montminy M, Verma IM 1990 Both the basic region and the 'leucine zipper' domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. *Embo J* 9:225-232
123. Ivashkiv LB, Liou HC, Kara CJ, Lamph WW, Verma IM, Glimcher LH 1990 mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. *Mol Cell Biol* 10:1609-1621
124. Kindy MS, Verma IM 1990 Developmental expression of the *Xenopus laevis* fos protooncogene. *Cell Growth Differ* 1:27-37
125. Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM 1990 Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation. *Proc Natl Acad Sci U S A* 87:4320-4324
126. Li CL, Dwarki VJ, Verma IM 1990 Expression of human α - and mouse/human hybrid β -globin genes in murine hemopoietic stem cells transduced by recombinant retroviruses. *Proc Natl Acad Sci USA* 87:4349-4353
127. Ofir R, Dwarki VJ, Rashid D, Verma IM 1990 Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter. *Nature* 348:80-82
128. Ransone LJ, Verma IM 1990 Nuclear proto-oncogenes fos and jun. *Annu Rev Cell Biol* 6:539-557
129. Ransone LJ, Visvader J, Wamsley P, Verma IM 1990 Trans-dominant negative mutants of Fos and Jun. *Proc Natl Acad Sci U S A* 87:3806-3810
130. Ransone LJ, Wamsley P, Morley KL, Verma IM 1990 Domain swapping reveals the modular nature of Fos, Jun, and CREB proteins. *Mol Cell Biol* 10:4565-4573
131. Sassone-Corsi P, Ransone LJ, Verma IM 1990 Cross-talk in signal transduction: TPA-inducible factor jun/AP-1 activates cAMP-responsive enhancer elements. *Oncogene* 5:427-431
132. Schule R, Rangarajan P, Klierer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans RM 1990 Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. *Cell* 62:1217-1226
133. Tratner I, De Togni P, Sassone-Corsi P, Verma IM 1990 Characterization and purification of human fos protein generated in insect cells with a baculoviral expression vector. *J Virol* 64:499-508
134. Verma IM 1990 Gene therapy. *Sci Amer* 262:68-84
135. Wisdom R, Verma IM 1990 Revertants of v-fos-transformed rat fibroblasts: suppression of transformation is dominant. *Mol Cell Biol* 10:5626-5633
136. Inoue J, Kerr LD, Ransone LJ, Bengal E, Hunter T, Verma IM 1991 c-rel activates but v-rel suppresses transcription from kappa B sites. *Proc Natl Acad Sci U S A* 88:3715-3719

137. Kerr LD, Inoue J, Davis N, Link E, Baeuerle PA, Bose HR, Verma IM 1991 The Rel-associated pp40 protein prevents DNA binding of rel and NF- κ B - Relationship with I-kappa-B-Beta and regulation by phosphorylation. *Genes & Dev* 5:1464-1476
138. Ofir R, Dwarki VJ, Rashid D, Verma IM 1991 CREB represses transcription of fos promoter: role of phosphorylation. *Gene Expr* 1:55-60
139. Scharfmann R, Axelrod JH, Verma IM 1991 Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. *Proc Natl Acad Sci U S A* 88:4626-4630
140. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM, Evans RM 1991 Retinoic acid is a negative regulator of AP-1-responsive genes. *Proc Natl Acad Sci U S A* 88:6092-6096
141. Tratner I, Ofir R, Verma IM 1991 Alteration of a cyclic AMP-dependent protein kinase phosphorylation site in the c-Fos protein augments its transforming potential. *Mol Cell Biol* 12:998-1006
142. Verma IM, Naviaux RK 1991 Human gene therapy. *Curr Opin Genet Dev* 1:54-59
143. Yen J, Wisdom RM, Tratner I, Verma IM 1991 An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins. *Proc Natl Acad Sci U S A* 88:5077-5081
144. Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, Verma IM 1992 Functional antagonism between c-Jun and MyoD proteins: a direct physical association. *Cell* 68:507-519
145. Dai Y, Roman M, Naviaux RK, Verma IM 1992 Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. *Proc Natl Acad Sci USA* 89:10892-10895
146. Day Y, Roman M, Naviaux RK, Verma IM 1992 Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. *Proc Natl Acad Sci USA* 89:10892-10895
147. Inoue J, Kerr LD, Kakizuka A, Verma IM 1992 I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. *Cell* 68:1109-1120
148. Inoue J, Kerr LD, Rashid D, Davis N, Bose HR, Jr., Verma IM 1992 Direct association of pp40/I kappa B beta with rel/NF-kappa B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity. *Proc Natl Acad Sci U S A* 89:4333-4337
149. Kerr LD, Duckett CS, Wamsley P, Zhang Q, Chiao P, Nabel G, McKeithan TW, Baeuerle PA, Verma IM 1992 The proto-oncogene bcl-3 encodes an I kappa B protein. *Genes Dev* 6:2352-2363
150. Kerr LD, Inoue J, Verma IM 1992 Signal transduction: the nuclear target. *Curr Opin Cell Biol* 4:496-501
151. Link E, Kerr LD, Schreck R, Zabel U, Verma I, Baeuerle PA 1992 Purified I kappa B-beta is inactivated upon dephosphorylation. *J Biol Chem* 267:239-246
152. Miyanojara A, Johnson PA, Elam RL, Dai Y, Witzum JL, Verma IM, Friedmann T 1992 Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX. *New Biol* 4:238-246
153. Morgan IM, Ransone LJ, Bos TJ, Verma IM, Vogt PK 1992 Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos. *Oncogene* 7:1119-1125
154. Naughton BA, Dai Y, Sibanda B, Scharfmann R, San Roman J, Zeigler F, Verma IM 1992 Long-term expression of a retrovirally introduced beta-galactosidase gene in rodent cells implanted in vivo using biodegradable polymer meshes. *Somat Cell Mol Genet* 18:451-462
155. Roman M, Axelrod JH, Dai Y, Naviaux RK, Friedmann T, Verma IM 1992 Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. *Somat Cell Mol Genet* 18:247-258
156. Verma IM, Inoue J, Kerr LD, Ofir R, Ransone LJ 1992 Oncogenes as transcription factors: implications for signal transduction. *Prog Clin Biol Res* 376:41-59
157. Wisdom R, Yen J, Rashid D, Verma IM 1992 Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains. *Genes Dev* 6:667-675
158. Dwarki VJ, Malone RW, Verma IM 1993 Cationic liposome-mediated RNA transfection. *Methods Enzymol* 217:644-654
159. Kerr LD, Ransone LJ, Wamsley P, Schmitt MJ, Boyer TG, Zhou Q, Berk AJ, Verma IM 1993 Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF- κ B. *Nature* 365:412-419
160. Leveillard T, Verma IM 1993 Diverse molecular mechanisms of inhibition of NF-kappa B/DNA binding complexes by I kappa B proteins. *Gene Expr* 3:135-150
161. Nabel GJ, Verma IM 1993 Proposed NF- κ B/I-Kappa-B Family Nomenclature. *Genes & Development* 7:2063-2063

162. Polak M, Scharfmann R, Seilheimer B, Eisenbarth G, Dressler D, Verma IM, Potter H 1993 Nerve growth factor induces neuron-like differentiation of an insulin-secreting pancreatic beta cell line. *Proc Natl Acad Sci U S A* 90:5781-5785
163. Ransone LJ, Kerr LD, Schmitt MJ, Wamsley P, Verma IM 1993 The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein. *Gene Expr* 3:37-48
164. Wisdom R, Verma IM 1993 Proto-oncogene FosB: the amino terminus encodes a regulatory function required for transformation. *Mol Cell Biol* 13:2635-2643
165. Wisdom R, Verma IM 1993 Transformation by Fos proteins requires a C-terminal transactivation domain. *Mol Cell Biol* 13:7429-7438
166. Bengal E, Flores O, Rangarajan PN, Chen A, Weintraub H, Verma IM 1994 Positive control mutations in the MyoD basic region fail to show cooperative DNA binding and transcriptional activation in vitro. *Proc Natl Acad Sci U S A* 91:6221-6225
167. Cauley K, Verma IM 1994 κ B enhancer-binding complexes that do not contain NF- κ B are developmentally regulated in mammalian brain. *Proc Natl Acad Sci USA* 91:390-394
168. Chiao PJ, Miyamoto S, Verma IM 1994 Autoregulation of I kappa B alpha activity. *Proc Natl Acad Sci U S A* 91:28-32
169. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BR, Torrence PF, Silverman RH 1994 Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. *Science* 265:789-792
170. Miyamoto S, Chiao PJ, Verma IM 1994 Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. *Mol Cell Biol* 14:3276-3282
171. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM 1994 Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. *Proc Natl Acad Sci U S A* 91:12740-12744
172. Miyamoto S, Schmitt MJ, Verma IM 1994 Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. *Proc Natl Acad Sci U S A* 91:5056-5060
173. Miyamoto S, Verma IM 1994 Rel/NF- κ B/I κ B story. *Advances in Cancer Research* 66:255-292
174. Stevens CF, Verma I 1994 Memory. A model with good CREdentials. *Curr Biol* 4:736-738
175. Verma IM 1994 Gene Therapy: Hope, hype and hurdles. *Molecular Medicine* 1:2-3
176. Barroga CF, Stevenson JK, Schwarz EM, Verma IM 1995 Constitutive phosphorylation of I kappa B alpha by casein kinase II. *Proc Natl Acad Sci U S A* 92:7637-7641
177. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM 1995 Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. *Proc Natl Acad Sci USA* 92:1401-1405
178. Miyamoto S, Cauley K, Verma IM 1995 Ultraviolet cross-linking of DNA binding proteins. *Methods Enzymol* 254:632-641
179. Somia N, Zoppe M, Verma I 1995 Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. *Proc Natl Acad Sci U S A* 92:7570-7574
180. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S 1995 Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. *Genes Dev* 9:2723-2735
181. Chapman MS, Verma IM 1996 Transcriptional activation by BRCA1. *Nature* 382:678-679
182. Naldini L, Blomer U, Gage F, Trono D, Verma I 1996 Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. *Proc Natl Acad Sci U S A* 93:11382-11388
183. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D 1996 In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* 272:263-267
184. Naviaux RK, Costanzi E, Haas M, Verma IM 1996 The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. *J Virol* 70:5701-5705
185. Schwarz EM, Van Antwerp DJ, Verma IM 1996 Constitutive phosphorylation of I kappa B alpha by casein kinase II occurs preferentially on serine 293: Requirement for degradation of free I kappa B alpha. *Mol Cell Biol* 16:3554-3559
186. Van Antwerp D, Verma IM 1996 Signal-induced degradation of I κ B α : association with NF- κ B and the PEST sequence in I κ B α are not required. *Mol Cell Biol* 16:6037-6045

187. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM 1996 Suppression of TNF- α -induced apoptosis by NF- κ B. *Science* 274:787-789
188. Blömer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH 1997 Highly efficient and sustained gene transfer in adult neurons with a lentiviral vector. *J Virol* 71:6641-6649
189. Carrozza ML, Jacobs H, Acton D, Verma I, Berns A 1997 Overexpression of the FosB2 gene in thymocytes causes aberrant development of T cells and thymic epithelial cells. *Oncogene* 14:1083-1091
190. Kafri T, Blömer U, Gage FH, Verma IM 1997 Sustained expression of genes delivered directly in liver and muscle by lentiviral vectors. *Nat Gen* 17:314-317
191. Miyoshi H, Takahashi M, Gage FH, Verma IM 1997 Stable and efficient gene transfer into the retina using a lentiviral vector. *Proc Natl Acad Sci USA* 94:10319-10323
192. Ruffner H, Verma IM 1997 BRCA1 is a cell cycle-regulated nuclear phosphoprotein. *Proc Natl Acad Sci USA* 94:7138-7143
193. Schwarz EM, Krimpenfort P, Berns A, Verma IM 1997 Immunological defects in mice with a targeted disruption in Bcl-3. *Genes & Dev* 11:187-197
194. Tashiro K, Pando MP, Kanegae Y, Wamsley PM, Inoue S, Verma IM 1997 Direct involvement of the ubiquitin-conjugating enzyme Ubc9/Hus5 in the degradation of I κ B α . *Proc Natl Acad Sci USA* 94:7862-7867
195. Verma IM, Somia N 1997 Gene therapy: promises, problems and prospects. *Nature* 389:239-242
196. Verma IM, Stevenson J 1997 I κ B kinase: Beginning, not the end. *Proc Natl Acad Sci USA* 94:11758-11760
197. Wang L, Zoppé M, Hackeng TM, Griffin JH, Lee K-F, Verma IM 1997 A factor IX-deficient mouse model for hemophilia B gene therapy. *Proc Natl Acad Sci USA* 94:11563-11566
198. Blömer U, Kafri T, Randolph-Moore L, Verma IM, Gage FH 1998 Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. *Proc Natl Acad Sci USA* 95:2603-2608
199. Gallichan WS, Kafri T, Krah T, Verma IM, Sarvetnick N 1998 Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulinitis. *Hum Gene Therap* 9:2717-2726
200. Kafri T, Morgan D, Krah T, Sarvetnik N, Sherman L, Verma I 1998 Cellular immune response to adenoviral vector infected cells does not require *de novo* viral gene expression: implications for gene therapy. *Proc Natl Acad Sci USA* 95:11377-11382
201. Kanegae Y, Tavares AT, Izpisua Belmonte JC, Verma IM 1998 Role of Rel/NF- κ B transcription factors during the outgrowth of the vertebrate limb. *Nature* 392:611-614
202. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM 1998 Development of a self-inactivating lentivirus vector. *J Virol* 72:8150-8157
203. Naldini L, Verma IM 1998 Lentiviral vectors. In: Friedman T ed. *The Development of Human Gene Therapy*. Cold Spring Harbor: CSHL Press; 47-60
204. Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU 1998 NF- κ B-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. *J Virol* 72:5654-5660
205. Van Antwerp DJ, Martin SJ, Verma IM, Green DR 1998 Inhibition of TNF-induced apoptosis by NF- κ B. *Trends in Cell Biol* 8:107-111
206. Kafri T, Praag HV, Ouyang L, Gage FH, Verma IM 1999 A packaging cell line for lentivirus vectors. *J Virol* 73:576-584
207. Li Q, Lu Q, Hwang JY, Büscher D, Lee K-F, Izpisua-Belmonte JC, Verma IM 1999 IKK1-deficient mice exhibit abnormal development of skin and skeleton. *Genes & Dev* 13:1322-1328
208. Li Q, Van Antwerp D, Mercurio F, Lee K-F, Verma IM 1999 Severe liver degeneration in mice lacking the I κ B kinase 2 gene. *Science* 284:321-325
209. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE 1999 Transduction of human CD34⁺ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. *Science* 283:682-686
210. Naldini L, Verma IM 1999 Lentiviral vectors. In: Friedmann T ed. *The Development of Human Gene Therapy*. New York: Cold Spring Harbor Laboratory Press; 47-60
211. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM 1999 BRCA1 is phosphorylated at serine 1497 *in vivo* at a cyclin-dependent kinase 2 phosphorylation site. *Molec Cell Biol* 19:4843-4354

212. Somia NV, Schmitt MJ, Vetter DE, Van Antwerp D, Heinemann SF, Verma IM 1999 LFG: a novel anti-apoptotic gene that protects from Fas mediated cell death. *Proceedings of the National Academy of Sciences (USA)* 96:12667-12672
213. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM 1999 Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. *Proceedings of the National Academy of Sciences (USA)* 96:13920-13925
214. Takahashi M, Miyoshi H, Verma IM, Gage FH 1999 Rescue from photoreceptor degeneration in the *rd* mouse by human immunodeficiency virus vector-mediated gene transfer. *J Virol* 73:7812-7816
215. Wang L, Takabe K, Bidlingmaier SM, III CR, Verma IM 1999 Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. *Proceedings of the National Academy of Sciences (USA)* 96:3906-3910
216. Blomer U, Verma IM, Gage FH 2000 Gene transfer to the central nervous system. In: Smyth Templeton N, Lasic DD eds. *Gene Therapy: Therapeutic Mechanisms and Strategies*. New York, NY: Marcel Dekker, Inc.; 489-506
217. Kafri T, van Praag H, Gage FH, Verma IM 2000 Lentiviral vectors: regulated gene expression. *Mol Ther* 1:516-521
218. Li Q, Estepa G, Memet S, Israel A, Verma IM 2000 Complete lack of NF- κ B activity in IKK1 and IKK2 double deficient mice: Additional defect in neurulation. *Genes Dev* 14:1729-1733
219. Naldini L, Verma IM 2000 Lentiviral Vectors. In: Glorioso J ed. *Advances in Virus Research*. San Diego: Academic Press; 599-606
220. Pando MP, Verma IM 2000 Signal dependent and independent degradation of free and NF- κ B bound I κ B α . *Mol Cell Biol* 20:21278-21286
221. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM 2000 CBP/p300 interact with and function as transcriptional coactivators of BRCA1. *Proceedings of the National Academy of Sciences (USA)* 97:1020-1025
222. Pfeifer A, Kessler T, Silletti S, Cheresch DA, Verma IM 2000 Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. *Proceedings of the National Academy of Sciences (USA)* 97:12227-12232
223. Somia N, Verma IM 2000 Gene therapy: trials and tribulations. *Nat Rev Genet* 1:91-99
224. Somia NV, Miyoshi H, Schmitt MJ, Verma IM 2000 Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping. *J Virol* 74:4420-4424
225. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM 2000 Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. *Mol Ther* 1:154-158
226. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM 2001 Delivery of the Cre recombinase by a self-deleting lentiviral vector: Efficient gene targeting *in vivo*. *Proceedings of the National Academy of Sciences (USA)* 10:1073-1078
227. Pfeifer A, Kessler T, Yang M, Baranov E, Kootstra N, Cheresch DA, Hoffman RM, Verma IM 2001 Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. *Mol Ther* 3:319-322
228. Pfeifer A, Verma IM 2001 Virus vectors and their applications. In: Howley P, Knipe D, Griffin D, Lamb RA, Martin A, Roizman B, Straus S eds. *Fields Virology*, 4th Edition. 4 ed. Philadelphia: Lippincott, Williams & Wilkins; 469-491
229. Pfeifer A, Verma IM 2001 Gene therapy: Promises and problems. *Annu Rev Genomics Hum Genet* 2:177-211
230. Ruffner H, Joazeiro CAP, Hemmati D, Hunter T, Verma IM 2001 Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. *Proceedings of the National Academy of Sciences (USA)* 98:5134-5139
231. Xu K, Ma H, McCown TJ, Verma IM, Kafri T 2001 Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. *Mol Ther* 3:97-104
232. Galimi F, Noll M, Kanazawa Y, Lax T, Chen C, Grompe M, Verma IM 2002 Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. *Blood* 100:2732-2736
233. Ikawa M, Tergaonkar V, Ogura A, Ogonuki N, Inoue K, Verma IM 2002 Restoration of spermatogenesis by lentiviral gene transfer: offspring from infertile mice. *Proceedings of the National Academy of Sciences (USA)* 99:7524-7529


234. Leal AMO, Takabe K, Wang L, Donaldson CJ, MacConell LA, Bilezikjian LM, Verma IM, Vale W 2002 Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo. *Endocrinology* 143:964-969
235. Li Q, Verma IM 2002 NF- κ B regulation in the immune system. *Nature Reviews Immunology* 2:725-734
236. MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, Wilson JM, Verma IM, Flake AW 2002 Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. *Mol Ther* 6:349-358
237. Pfeifer A, Ikawa M, Dayn Y, Verma IM 2002 Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. *Proceedings of the National Academy of Sciences (USA)* 99:2140-2145
238. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I 2002 p53 stabilization is decreased upon NF κ B activation; A role for NF κ B in acquisition of resistance to chemotherapy. *Cancer Cell* 1:493-503
239. Gage FH, Verma IM 2003 Stem cells at the dawn of the 21st century. *Proc Natl Acad Sci U S A* 100:11817-11818
240. Ikawa M, Tanaka N, Kao WWY, Verma IM 2003 Generation of transgenic mice using lentiviral vectors: a novel pre-clinical assessment of lentiviral vectors for gene therapy. *Mol Ther* 8:666-673
241. Kanazawa Y, Verma IM 2003 Little evidence of bone marrow-derived hepatocytes in the replacement of injured liver. *Proc Natl Acad Sci U S A* 100:11850-11853
242. Kootstra N, Verma IM 2003 Gene therapy with viral vectors. *Ann Rev Pharmacol Toxicol* 43:413-439
243. Kootstra NA, Matsumura R, Verma IM 2003 Efficient production of human FVIII in hemophilic mice using lentiviral vectors. *Mol Ther* 7:623-631
244. Kootstra NA, Münk C, Tonnu N, Landau NR, Verma IM 2003 Abrogation of post-entry restriction of HIV-1 based lentiviral vector transduction in simian cells. *Proceedings of the National Academy of Sciences (USA)* 100:1298-1303
245. Marr RA, Rockenstein E, Mukherjee A, Hersh LB, Gage FH, Verma IM, Maslian E 2003 Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. *J Neurosci* 23:1992-1996
246. Shin S, Verma IM 2003 BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. *Proc Natl Acad Sci U S A* 100:7201-7206
247. Takabe K, Wang L, Leal AMO, MacConell LA, Waiter E, Tomoaki T, Ohno A, Verma IM, Vale W 2003 Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. *Hepatology* 38:1107-1115
248. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM 2003 I κ B kinase independent I κ B α degradation pathway: functional NF- κ B activity and implications for cancer therapy. *Mol Cell Biol* 23:8070-8083
249. Tiscornia G, Singer O, Ikawa M, Verma IM 2003 A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. *Proceedings of the National Academy of Sciences (USA)* 100:1844-1848
250. Verma IM 2003 Gene Therapy: Medicine of the 21st Century. In: Mallet J, Christen Y eds. *Neurosciences at the Postgenomic Era*. Berlin Heidelberg: Springer-Verlag; 159-172
251. Xia Y, Pao GM, Chen HW, Verma IM, Hunter T 2003 Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. *J Biol Chem* 278:5255-5263
252. Correa RG, Tergaonkar V, Ng JK, Dubova I, Izpisua-Belmonte JC, Verma IM 2004 Characterization of NF- κ B/I κ B proteins in zebra fish and their involvement in notochord development. *Mol Cell Biol* 24:5257-5268
253. Ducut Sigala JL, Bottero V, Young DB, Shevchenko A, Mercurio F, Verma IM 2004 Activation of transcription factor NF- κ B requires ELKS, an I κ B kinase regulatory subunit. *Science* 304:1963-1967
254. Galimi G, Saez E, Gall J, Hoong N, Cho G, Evans RM, Verma IM 2004 Development of ecdysone-regulated lentiviral vectors. *Mol Ther* 11:142-148
255. Kankkonen HM, Vahakangas E, Marr RA, Pakkanen T, Laurema A, Leppanen P, Jalkanen J, Verma IM, Yla-Herttuala S 2004 Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. *Mol Ther* 9:548-556
256. Marr RA, Guan H, Rockenstein E, Kindy MS, Gage FH, Verma I, Maslian E, Hersh LB 2004 Neprilysin regulates amyloid β peptide levels. *J Mol Neurosci* 22:5-12
257. Singer O, Yanai A, Verma IM 2004 Silence of the genes (Commentary). *Proc Natl Acad Sci* 101:5313-5314

258. Tiscornia G, Tergaonkar V, Galimi F, Verma IM 2004 CRE recombinase-inducible RNA interference mediated by lentiviral vectors. *Proc Natl Acad Sci* 101:7347-7351
259. Verma IM 2004 Nuclear factor (NF)-kappaB proteins: therapeutic targets. *Ann Rheum Dis* 63 Suppl 2:ii57-ii61
260. Correa RG, Matsui T, Tergaonkar V, Rodriguez-Esteban C, Izpisua-Belmonte JC, Verma IM 2005 Zebrafish IkappaB kinase 1 (Ikk1) negatively regulates NF-kappaB activity. *Curr Biol* 15:1291-1295
261. Dhawan J, Gokhale RS, Verma IM 2005 Bioscience in India: Times are changing (Commentary). *Cell* 123:743-745
262. Dodart J-C, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM 2005 Gene delivery of human apolipoprotein E alters brain A β burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci* 102:1211-1216
263. Galimi F, Summers RG, van Praag H, Verma IM, Gage FH 2005 A role for bone marrow-derived cells in the vasculature of noninjured CNS. *Blood* 105:2400-2402
264. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, Schadt EE, Ellison JA, Verma IM, Lockhart DJ, Barlow C 2005 Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. *Nature* 438:662-666
265. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM 2005 Enhanced NF-kB activation and cellular function in macrophages lacking I κ B kinase 1 (IKK1). *Proc Natl Acad Sci* 102:12425-12430
266. Li Q, Lu Q, Estepa G, Verma IM 2005 Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. *Proc Natl Acad Sci U S A* 102:15977-15982
267. Li Q, Withoff S, Verma IM 2005 Inflammation-associated cancer: NF-kB is the lynchpin. *Trends in Immunology* 28:318-325
268. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E 2005 Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. *Nature Neurosci* 8:1343-1349
269. Singer O, Tiscornia G, Verma I 2005 siRNA delivery by lentiviral vectors: Design and applications. In: Appasani K ed. *RNA Interference Technology*. Cambridge: Cambridge University Press; 174-185
270. Tergaonkar V, Correa RG, Ikawa M, Verma IM 2005 Distinct roles of IkappaB proteins in regulating constitutive NFkappaB activity. *Nature Cell Biology* 7:921-923
271. Verma IM 2005 Nature Outlook: INDIA. *Nature* 436:477-498
272. Verma IM, Weitzman WD 2005 Gene therapy: Twenty-first century medicine. *Annu Rev Biochem* 74:711-738
273. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM 2005 Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. *Blood* 105:3079-3086
274. Bottero V, Withoff S, Verma IM 2006 NF-kappaB and the regulation of hematopoiesis. *Cell Death Differ* 13:785-797
275. Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Pist P, Verma IM, Hunter T 2006 Essential role of tuberous sclerosis genes *TSC1* and *TSC2* in NF-kB activation and cell survival. *Cancer Cell* 10:215-226
276. Liao W, Nguyen MT, Imamura T, Singer O, Verma IM, Olefsky JM 2006 Lentiviral short hairpin ribonucleic acid-mediated knockdown of GLUT4 in 3T3-L1 adipocytes. *Endocrinology* 147:2245-2252
277. Singer O, Tiscornia G, Masahito I, Verma IM 2006 Rapid generation of knockdown transgenic mice by silencing lentiviral vectors. *Nat Prot publ on-line* 6/27/06
278. Tanaka N, Ikawa M, Mata NL, Verma IM 2006 Choroidal neovascularization in transgenic mice expressing prokineticin 1: an animal model for age-related macular degeneration. *Molecular Therapy* 13:609-161
279. Tergaonkar V, Li Q, Verma IM 2006 Inhibitors of NFkB activity: tools for treatment of human ailments. In: Liou H-C ed. *NFkB/Rel Transcription Factor Family*: Landes/Eurekah
280. Tiscornia G, Singer O, Verma IM 2006 Design and cloning of lentiviral vectors expressing small interfering RNAs. *Nat Prot publ on-line* 6/27/06
281. Woods N-B, Bottero V, Verma IM 2006 Gene therapy: therapeutic gene causing lymphoma. *Nature* 440:1123
282. Hoffman A, Xia Y, Verma IM 2007 Inflammatory tales of liver cancer. *Cancer Cell* 11:99-101
283. Spencer B, Verma IM 2007 Targeted delivery of proteins across the blood-brain barrier. *Proc Natl Acad*

Exhibit 2
of Dr. Verma Declaration
filed October 19, 2007 in

Applicant: David Baltimore et al.
Serial No.: 10/037,341
Filed: January 4, 2002

prior to following CsA administration



TF

GAPDH



Exhibit B
of Amendment in Response to April 19, 2007 Office
Action, Petition for a Three-Month Extension of Time
And Information Disclosure Statement
filed October 19, 2007 in

Applicant: David Baltimore et al.
Serial No.: 10/037,341
Filed: January 4, 2002